Contineum Q2 net loss $15.2M; cash $236.6M; workforce reduction includes CSO departure

Contineum Therapeutics, Inc.

Net loss of $15.2M vs $16.0M in Q2 2025; R&D expense $12.7M (-10% YoY); G&A $4.7M (+23% YoY).
Cash, equivalents and marketable securities $236.6M; runway projected through mid-2029.
Workforce reduction in research team; CSO Daniel Lorrain, Ph.D. departing.
PROPEL-IPF Phase 2 trial of PIPE-791 ongoing with >55 sites in 8 countries; J&J completed enrollment in Phase 2 MDD trial of JNJ-5120/PIPE-307.
Positive Phase 1b topline data for PIPE-791 in chronic pain; safety consistent with prior trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.